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Abstract
Background: Mass spectrometry is increasingly being used to discover proteins or protein profiles associated with
disease. Experimental design of mass-spectrometry studies has come under close scrutiny and the importance of strict
protocols for sample collection is now understood. However, the question of how best to process the large quantities
of data generated is still unanswered. Main challenges for the analysis are the choice of proper pre-processing and
classification methods. While these two issues have been investigated in isolation, we propose to use the classification
of patient samples as a clinically relevant benchmark for the evaluation of pre-processing methods.
Results: Two in-house generated clinical SELDI-TOF MS datasets are used in this study as an example of high throughput
mass-spectrometry data. We perform a systematic comparison of two commonly used pre-processing methods as
implemented in Ciphergen ProteinChip Software and in the Cromwell package. With respect to reproducibility,
Ciphergen and Cromwell pre-processing are largely comparable. We find that the overlap between peaks detected by
either Ciphergen ProteinChip Software or Cromwell is large. This is especially the case for the more stringent peak
detection settings. Moreover, similarity of the estimated intensities between matched peaks is high.
We evaluate the pre-processing methods using five different classification methods. Classification is done in a double
cross-validation protocol using repeated random sampling to obtain an unbiased estimate of classification accuracy. No
pre-processing method significantly outperforms the other for all peak detection settings evaluated.
Conclusion: We use classification of patient samples as a clinically relevant benchmark for the evaluation of pre-
processing methods. Both pre-processing methods lead to similar classification results on an ovarian cancer and a
Gaucher disease dataset. However, the settings for pre-processing parameters lead to large differences in classification
accuracy and are therefore of crucial importance. We advocate the evaluation over a range of parameter settings when
comparing pre-processing methods. Our analysis also demonstrates that reliable classification results can be obtained
with a combination of strict sample handling and a well-defined classification protocol on clinical samples.
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With the use of mass spectrometry techniques such as
MALDI-TOF and SELDI-TOF, it has become possible to
analyse complex protein mixtures as found in serum rela-
tively quickly. This has led to the discovery of a large
number of proteins and protein profiles associated with
various types of diseases [1-4]. However, after promising
initial reports important questions have been raised about
the reproducibility and reliability of the technique [5].
Reasons for these shortcomings range from pre-analytical
effects like sample storage and number of freeze-thaw
cycles [6] to the analytical problems of bias due to overfit-
ting and lack of external validation. As a result research
moved forward towards the formulation of study require-
ments and adequate standards in clinical proteomics [7-
9]. One of these efforts towards standardization of pre-
analytical variables is now being undertaken by the Spec-
imen Collection and Handling Committee of the HUPO
Plasma Proteome Project [10].
In this study we investigate some of the problems associ-
ated with the generation and analysis of SELDI-TOF MS
datasets. In order to eliminate potential pre-analytical
biases due to sample handling, we used strict protocols for
sample collection, storage and experiments [10].
Pre-processing is the first essential step in the analysis of
mass spectrometry generated data. Inadequate pre-
processing has been shown to have a negative effect on the
reproducibility of biomarker identification and the extrac-
tion of clinically useful information [11,12]. Since there is
no generally accepted approach to pre-processing, differ-
ent methods have been proposed, for example [13-17].
Given the large number of existing pre-processing tech-
niques, one would like to know which one is most effec-
tive. Therefore, the comparison of pre-processing
techniques has recently gained new interest. Cruz-Marcelo
et al. [18] and Emanuele et al [19] compared five and nine,
pre-processing methods respectively. However, these
studies evaluate the strengths and weaknesses of the dif-
ferent methods on simulated data and quality control
datasets. Moreover, the performance of a pre-processing
method is only evaluated in terms of reproducibility
(coefficient of variation) and sensitivity/specificity of
peak detection. While providing important information,
our goal in this paper is to compare pre-processing meth-
ods in a clinical setting with a relevant and measurable
objective. A realistic clinical setting is provided for by in-
house ovarian cancer and Gaucher disease profiling data-
sets and our objective is to maximize classification per-
formance across five different classification methods. We
compare the method implemented in Ciphergen Protein-
Chip Software 3.1 with the mean spectrum technique
from the Cromwell package [5] in a classification setting.
Ciphergen was included since it is still the most com-
monly used program by researchers processing their data.
Cromwell was included since it showed promising results
as a viable alternative to the Ciphergen software [5]. More-
over, these two preprocessing packages were consistently
among the top three performers in the recent benchmark
studies of Cruz-Marcelo et al. [18] and Emanuele et al [19]
mentioned above. Classification methods have been
benchmarked on mass spectrometry data before [20,21],
however in general using only one pre-processing method
[22]. Recently, Meuleman et al [23] showed that the nor-
malization step alone already has a significant influence
on classification accuracy. Our analysis extends this to an
investigation of the influence of the entire pre-processing
pipeline and different parameter settings on classification
accuracy.
The past few years, both in the microarray [24] and the
proteomics [20] field, the importance of proper classifica-
tion protocols has been pointed out. Core ingredients of
such a protocol are (i) complete separation of training
data used for estimating the parameters of a model and
test data for estimating the accuracy of the model, (ii)
multiple estimates of classification accuracy to be able to
assess its variance, and (iii) cross-validation on the train-
ing data to determine optimal values for hyperparameters
of a model and to select features. In this paper, we propose
to implement this by a double cross-validation scheme
that provides an almost unbiased estimate of the true
error.
Combining all of these protocols, ranging from sample
collection via pre-processing to classification, we aimed to
develop the optimal strategy for analyzing complex mass
spectrometry generated datasets such as SELDI-TOF MS
datasets.
Methods
Samples
For both the ovarian cancer and Gaucher disease data,
serum samples were obtained from participating newly
diagnosed patients admitted at the Academic Medical
Center (AMC) after informed consent was obtained. The
study was performed in agreement with the Helsinki Dec-
laration and approved by the Ethical Committee at the
Academic Medical Center, University of Amsterdam.
The group of newly diagnosed non-familial epithelial
ovarian carcinoma patients consisted of 14 persons of
whom 2 patients had stage I/II invasive epithelial ovarian
cancer and 12 patients had stage III/IV epithelial ovarian
cancer based on FIGO (Fédération Internationale de
Gynécologie Obstétrique) criteria. Among the 14 patients
with ovarian carcinoma, 11 were serous, 2 were
endometroid and 1 was mucinous. Well-matched samples
of 14 patients with benign gynecological disease were alsoPage 2 of 17
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consisted of patients with a serous cystadenoma, mature
cystic teratoma, fibroma of the ovary or patients that
underwent an abdominal myomectomy. The two groups
were matched for age and body mass index (BMI). Mean
ages in the groups were 58 (range 27–71) for the ovarian
cancer patients and 59 (range 27–70) for the control
group. The mean BMI in the group of ovarian cancer
patients was 27.2 (range 17.6–42.1) as compared to 28.7
(range 19.5–53.4) in the control group. Both groups had
an equal distribution of pre- and post-menopausal
patients.
For the Gaucher dataset, patients with Gaucher disease
type I referred to the Academic Medical Center were
included. The group consisted of 10 males and 9 females,
15–65 years old. All patients were included before initia-
tion of therapy. The control group consisted of 7 male and
13 female healthy volunteers, 23–68 years old.
Samples from both ovarian cancer and Gaucher patients
were collected before treatment using a strict protocol.
Blood was collected in the morning at a minimum of two
hours after the patient's last meal and left to clot for thirty
minutes. After centrifugation (at 1750 × g) serum was
immediately frozen and stored at -80°C. Samples used for
these experiments were only thawed once.
SELDI-TOF MS
Plasma samples were analyzed using surface-enhanced
laser desorption/ionization (SELDI) time of flight (TOF)
mass spectrometry (MS). Samples from ovarian cancer
patients and controls were processed on the CM10 Pro-
teinChip array, a weak cation exchanger, and the Q10 Pro-
teinChip array, a strong anion exchanger (Ciphergen
Biosystems, Fremont, California, USA). Samples from
Gaucher patients and controls were only processed on
CM10 ProteinChip arrays. Samples were thawed and cen-
trifuged at 16,000 rpm for 5 minutes. 10 μl of each serum
sample was denatured in 90 μl U9 mix (2.2 M Thio/7.7 M
urea, 2% CHAPS (3 [(3-cholamidopropyl)dimethylam-
monio]-propane-sulfonicacid), and 1% dithiothreitol
(DTT)) at room temperature for 60 minutes. 10 μl of this
solution was mixed with 90 μl binding buffer (50 mM
phosphate buffer, pH 6.0, 0.1% Triton X-100) and added
to a CM10 ProteinChip array. For the Q10 ProteinChip
array 10 μL of this solution was mixed with 90 μL binding
buffer (50 mM Tris [tris(hydroxymethyl)aminomethane]
HCl, pH 8.0, 0.1% Triton X-100), before being added to
the ProteinChip array. Before incubation with serum sam-
ples, the ProteinChip arrays were washed twice for 5 min-
utes with binding buffer [25]. In both studies patient and
control samples were randomly allocated on each Protein-
Chip array to avoid confounding of the effect of interest
(patient versus control) with chip effects.
After 45 minutes incubation at room temperature the Pro-
teinChips were washed with binding buffer (2 times, 5
minutes). Next, the CM10 ProteinChip arrays were
washed with 50 mM phosphate buffer, pH 6 (2 times, 5
minutes) and the Q10 ProteinChip arrays with Tris buffer
pH 8 (2 times, 5 minutes). After the final buffer wash each
chip was quickly washed with HPLC-grade water and
allowed to dry. 5 μL of matrix (sinapinic acid (10 mg/ml)
in 50% acetonitrile and 1% trifluoroacetic acid) was
added to each spot on the ProteinChip array twice, allow-
ing the applied matrix solution to dry between applica-
tions.
The arrays were read on a PBSII reader (Ciphergen Biosys-
tems, Fremont, California, USA) with laser intensities of
175 (ovarian cancer) and 165 (Gaucher), a detector sensi-
tivity of 6 and a detection size range between 1.5 and 20
kDa (ovarian cancer), 1 and 10 kDa (Gaucher). The spec-
tra were calibrated using the All-in-one Peptide Molecular
Weight mix (Ciphergen Biosystems, Fremont, California,
USA). Peptides used for calibration were bovine Insulin β-
chain (3495 Da), Human Insulin (5807 Da) and Hirudin
BHVK (7033 Da). Calibration was performed once before
measuring the CM10 ProteinChip arrays in rapid succes-
sion. Q10 ProteinChip arrays were calibrated individually
by using a spot on every ProteinChip array for calibration
mixture.
Pre-processing and peak detection using ProteinChip 
Software
Pre-processing was done with the commercial Protein-
Chip Software (version 3.1.1, Ciphergen Biosystems) and
its Biomarker Wizard module. Baseline correction was
applied to all spectra. The algorithm is a modified piece-
wise convex-hull that attempts to find the bottom of the
spectra and correct the peak height and area [26]. Spectra
were normalized to the average total ion current (TIC) in
the mass range from 1.5 to 50 kDa (ovarian cancer), 1 to
10 kDa (Gaucher).
On the Gaucher dataset spot-to-spot calibration was per-
formed. A set of peaks that is present in all our spectra was
chosen to determine the correction factors for the differ-
ent positions on a ProteinChip array. The correction fac-
tors were applied to the corresponding mass spectra and
used in the recalculation of the masses.
Peak detection was performed with the Biomarker Wizard
module in the mass range from 1.5 to 50 kDa (ovarian
cancer), 1 to 10 kDa (Gaucher). Biomarker Wizard groups
peaks of similar molecular weight across spectra. The algo-
rithm is divided in two passes, the first pass detects well-
defined peaks with a high specificity and forms clusters
around them. In the second pass smaller peaks are added
to an existing cluster. Four parameters have to be specifiedPage 3 of 17
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(signal-to-noise ratio (S/N)), (ii) Min Peak Threshold (%
of all spectra), (iii) Cluster Mass Window (% of mass),
and (iv) Second Pass (S/N). The First Pass S/N threshold
specifies the sensitivity of the first pass of peak detection.
The Min Peak Threshold is the minimum number of spec-
tra, as a percentage of all spectra, in which a peak must be
present in order to form a cluster. A cluster will not be
formed around a peak if it is not present in the requisite
number of spectra, and the label is deleted. Cluster Mass
Window specifies the width of the mass window as a per-
centage of a peak's mass. This determines the width of a
cluster as a function of molecular weight. The Second Pass
S/N threshold specifies how to populate the clusters from
the first pass with peaks that were too small to be found
in the first pass.
For both datasets, we used three typical different peak
detection settings with increasing stringency (Ciphergen
A-C, Table 1) in Biomarker Wizard to evaluate the effect of
peak detection on classification outcome. Setting A was
chosen in such a way that many – potentially noisy –
peaks were detected. Settings B and C are more stringent
by increasing the signal-to-noise ratio of detected peaks or
the number of spectra in which a peak must be present.
This way we covered a broad range of detected peaks,
going from about 100 (setting C) to 500–800 (setting A).
Any peak intensity that was zero or negative after baseline
correction was set equal to half the minimum of the pos-
itive corrected intensities for that peak. Resulting peak
intensities were log2-transformed in order to stabilize
their variance. In the rest of the paper we will refer to these
pre-processing steps as Ciphergen pre-processing.
Pre-processing and peak detection using Cromwell 
software
Pre-processing was done with the publicly available
Cromwell software developed by the bioinformatics
group at the MD Anderson Cancer Center [14]. From the
raw spectra, a mean spectrum was calculated by averaging
all spectra. Smoothing of the mean spectrum was done via
wavelet denoising using the undecimated discrete wavelet
transform (UDWT). Because most signals can be repre-
sented by a small number of wavelet coefficients and
white noise is distributed equally among all wavelet coef-
ficients, this approach denoises spectra with minimal
attenuation of the features of the signal [5,14]. The UDWT
is invariant under linear shift. The wavelet smoothing
threshold was set at 10. Baseline correction was per-
formed by computing a monotonic local minimum curve
on the denoised signal. Normalization of the mean spec-
trum was done by dividing by the total ion current within
the given mass range. Peaks were identified from this
denoised, baseline corrected and normalized mean spec-
trum as a local maximum with S/N greater than a user-
defined threshold (see below) together with the nearest
local minima to the left and the right, respectively, of the
local maximum. The interval between the two bordering
minima of a peak in the average spectrum was used to
define peak positions.
Peaks identified from the mean spectrum were quantified
in the individual spectra. First, all spectra were denoised,
baseline corrected, and normalized. Individual smoothed
spectra were searched for the maximum within each peak
interval defined on the mean spectrum, taking the corre-
sponding intensity values as individual values for these
peaks. Resulting peak intensities were multiplied with a
factor 1000 to bring them on a similar scale as Ciphergen
data and then log2-transformed.
We adapted the Cromwell MATLAB (The Mathworks Inc,
Natick, Massachusetts, USA) scripts in various ways. A
script was written to read in the raw data (XML) into an
appropriate Matlab structure. Furthermore, in order to fit
an accurate baseline, the low-mass area of the spectra that
is saturated with matrix peaks was ignored using a con-
servative cut-off of 1500 Da (ovarian cancer dataset) or
1000 Da (Gaucher dataset). The spectra were also trun-
cated at their high-mass end with a cut-off of 50000 Da
(ovarian cancer dataset) or 10000 Da (Gaucher dataset).
This was done because a long noisy tail can bias smooth-
ing towards the noise. A further addition to the original
Cromwell software as described by Coombes et al. [14]
was made in the form of spectral alignment. Visual inspec-
tion showed that the individual spectra were not well
aligned (data not shown). A time warping alignment to
correct for horizontal shift was executed on the basis of
manually selected peaks using the function "msalign"
from the Matlab Bioinformatics toolbox. The peaks used
for alignment were m/z values 2750, 5914, 6441 and
6639 Da for CM10 and 4095 and 15946 Da for Q10
(ovarian cancer dataset) and 2735, 3391, 4170, and 9299
(Gaucher dataset).
Table 1: Peak detection settings used in Ciphergen pre-
processing
First pass Threshold Mass window Second pass
Ovarian cancer
Ciphergen A 5 30 0.3 2
Ciphergen B 10 30 0.3 5
Ciphergen C 12 40 0.4 5
Gaucher
Ciphergen A 2 20 0.3 1
Ciphergen B 3 30 0.3 2
Ciphergen C 5 30 0.3 2Page 4 of 17
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peak detection settings with increasing stringency for S/N.
We used S/N settings of 1, 3, and 5 (Cromwell A-C). This
way we covered a broad range of detected peaks, going
from about 100 (setting C) to 200–500 (setting A). Note
that a signal-to-noise ratio of 3–5 has been recommended
by the developers of Cromwell [14].
Datasets
For the ovarian cancer dataset, CM10 and Q10 Protein-
Chip array data were analyzed with three different pre-
processing settings for both Cromwell and Ciphergen (12
configurations). For each pre-processing method and set-
tings we also made a combined CM10/Q10 dataset by tak-
ing the union of the CM10 and Q10 peak intensities for
each sample (6 configurations). In total we therefore used
18 configurations for investigation of differential expres-
sion and prediction of patient status for cancer versus con-
trol. For the Gaucher dataset, CM10 ProteinChip array
data was analyzed with three different pre-processing set-
tings for both Cromwell and Ciphergen (6 configura-
tions).
Statistical Analysis
T-tests were used to identify differentially expressed peaks
between patient and control groups. Analysis of variance
(ANOVA) was also used to assess the importance of label
(patient versus control), chip (array), and interaction
effects between label and chip within the dataset. Result-
ing p-values were corrected for multiple testing using the
Benjamini-Hochberg False Discovery Rate (FDR) adjust-
ment [27]. Tests were considered to be significant if the
adjusted p-values were < 0.2.
Classification
To test whether patient status (control/diseased) can be
predicted from the peak profiles obtained, five classifica-
tion methods often used for microarray and proteomics
data were compared. The models are classification trees,
linear support vector machines (SVM), DLDA (Diagonal
Linear Discriminant Analysis), naive Bayes with Gaussian
class-conditional densities (Diagonal Quadratic Discrimi-
nant Analysis (DQDA)) [28] and PCDA (Principal Com-
ponent Discriminant Analysis) [29].
The models were validated with repeated random sam-
pling methodology as advocated by Michiels et al. [30].
Random splits of each dataset of N samples were per-
formed to generate 1000 (ovarian cancer dataset) or 500
(Gaucher dataset) different training sets (size n) and 1000
respectively 500 associated test sets (size N-n). In each of
the random splits, the number of samples for both classes
was balanced in both training and test set. The accuracy of
the resulting classifier was assessed on the corresponding
test set. We report average accuracy on the test sets and its
corresponding confidence interval. To investigate the
influence of the training set size on the accuracy of the
classifier, we also varied the training set size (n = 6,8,...,26
for the ovarian cancer dataset, n = 9,11,...,37 for Gaucher).
Estimation of the optimal values for hyperparameters of
the models was done with 5-fold cross-validation on the
training set. Such a double cross-validation scheme pro-
vides an almost unbiased estimate of the true error [31].
Hyperparameters to be estimated and their possible val-
ues were: complexity parameter (classification trees), cost
parameter (0.5,1,...,3; SVMs), number of principal com-
ponents (1–10; PCDA)
All classifiers were used under three different regimes. In
the first regime, all peaks are used to estimate the model
parameters. The second regime uses feature selection to
extract the peaks most informative for predicting patient
status. For each training set, an optimal classifier was iden-
tified from the 10, 20,...,50 peaks for which expression
was most highly correlated with disease as determined by
the t-statistics between the two classes. The optimal
number of peaks was again selected with 5-fold cross-val-
idation on the training set. In the third regime, class labels
were permuted to obtain an estimate of the performance
of the classifiers on random data. Statistical comparisons
for classifiers over multiple configurations were per-
formed with a non-parametric Friedman test for repeated
measures and the Wilcoxon-Nemenyi-McDonald-
Thompson post-hoc test [32]. Statistical analyses were
performed using Bioconductor packages and in-house
scripts in the statistical software package R [33].
Results
Peak detection: comparison of Ciphergen and Cromwell
For both Ciphergen and Cromwell pre-processing, three
different peak detection settings were chosen. More strin-
gent peak detection parameters indeed resulted in a
decrease in the number of peaks selected (Table 2). First,
we will illustrate differences in peak detection between
Table 2: Number of peaks after peak selection
Ovarian cancer Gaucher
CM10 Q10 CM10/Q10
Ciphergen A 776 742 1518 579
Ciphergen B 268 182 450 201
Ciphergen C 155 79 234 90
Cromwell A 383 226 609 501
Cromwell B 193 113 306 250
Cromwell C 118 70 188 162
Three different settings (A, B, C) were used for both Ciphergen and 
Cromwell pre-processing.Page 5 of 17
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from the ovarian cancer dataset.
Cromwell detects shoulders
Figure 1 shows an example of peaks detected by either
method visualized in a low-intensity region of the mean
raw spectrum. Here, all peaks detected by Ciphergen are
also detected by Cromwell. In addition, Cromwell detects
shoulder peaks near 7968 Da, 8000 Da, and 8023 Da. We
consider this to be an advantage of Cromwell since shoul-
der peaks might very well be biologically relevant and
could, for example, be the result of overlapping peaks for
peptides with similar mass.
Ciphergen detects low intensity peaks
Figure 2 illustrates that Ciphergen can detect peaks not
found by Cromwell. However, the low-intensity peak at
2733 Da, for example, is probably a spurious peak and
this was confirmed by visual inspection of the individual
spectra.
Cromwell detects peaks present in few samples
As Morris et al. [14] observed, Cromwell can still detect
peaks if they are only present in part of the spectra. Figure
3A gives an example of such a peak at 9740 Da that goes
undetected by Ciphergen. Inspection of the per spectrum
intensities of this peak shows that the main contribution
to the average spectrum comes from two peaks of moder-
ate intensity in the cancer group (Figure 3B). While such
peaks might be biologically interesting, we consider them
of less relevance as a potential biomarker because of their
large inter-individual variation.
Not withstanding these specific differences, generally the
overlap between the peaks detected by either Ciphergen or
Cromwell is large. We matched peaks x (Ciphergen) and y
(Cromwell) if | x - y | < max(0.004x, 0.004y), that is, if the
mass difference between the two peaks is less than 0.4%
of the mass of both peaks. The factor 0.004 was chosen
since it corresponds to the setting used for the 'Cluster
Mass Window' parameter in Ciphergen pre-processing
(Table 1). In this way, 105 out of 118 CM10 peaks
detected by Cromwell C could be matched to peaks
detected by Ciphergen C (ovarian cancer dataset). For the
Gaucher dataset, 82 out of 90 peaks detected by Cipher-
gen C could be matched to peaks detected by Cromwell C.
To assess the similarity of the peak intensities, the Pearson
correlation coefficient across all samples was calculated
for each matched peak pair. Similarity was high: for CM10
(setting C, ovarian cancer dataset) the median correlation
for the 105 matched peak pairs was 0.89 (range 0.27 –
Comparison of detected peaks (ovarian cancer dataset)Figure 1
Comparison of detected peaks (ovarian cancer data-
set). Plot of the mean (n = 28) raw spectrum illustrating dif-
ference in peaks detected by Ciphergen (setting C, orange) 
and Cromwell (setting C, green) pre- processing. Solid cir-
cles below peaks indicate the peak location.
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Comparison of mean raw spectra for cancer and control gr u sFig re 2
Comparison of mean raw spectra for cancer and con-
trol groups. Plot of the mean raw spectra calculated for 
cancer (n = 14, cyan line) and control (n = 14, dashed red 
line) groups. Solid circles below peaks indicate peaks 
detected by Ciphergen (setting B, orange) and Cromwell 
(setting B, green) pre-processing.
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the 82 matched peak pairs was 0.91 (range 0.0 – 0.98).
Similarity decreases when less strict peak detection set-
tings are used, e.g., for CM10 (setting A, ovarian cancer
dataset) the median correlation for the matched peaks is
0.63 (range -0.23 – 0.97).
Reproducibility of the pre-processed spectra was
addressed by calculating the coefficient of variation (CV)
over all peaks and all spectra (see Additional File 1 and
Additional File 2). The reproducibility is largely compara-
ble across pre-processing methods. There is a tendency of
Ciphergen pre-processing being less variable than
Cromwell on the ovarian cancer dataset, especially for the
more stringent parameter settings (p < 0.01 for both
CM10 and Q10 (setting C)). An opposite tendency was
observed on the Gaucher dataset with Cromwell pre-
processing being less variable than Ciphergen for the least
stringent parameter settings (p < 0.01, setting A).
Differential expression: comparison of Ciphergen and 
Cromwell
The correct identification of differentially expressed peaks
(corresponding to peptides or proteins) is highly relevant
for clinical datasets. Since both our datasets consist of two
biologically very distinct classes, we expect a good pre-
processing method to identify many peaks with a small
FDR when comparing patients and controls. Therefore, an
ANOVA was performed to assess the importance of label
(patient versus control), chip (array), and interaction
effects between label and chip. Both pre-processing meth-
ods led to a considerable number of peaks that are differ-
entially expressed between the patient and the control
group even when correcting for multiple testing (Table 3,
label effect). For Ciphergen pre-processing of the ovarian
cancer dataset, there was clear evidence of a chip effect for
a number of peaks. The effect was most pronounced for
the Q10 dataset (setting A): 57 peaks against 6 in the
CM10 dataset (Table 3, chip effect). A likely explanation
of the chip effect is the fact that Q10 arrays were calibrated
individually with respect to a calibration spot on the
array. Nevertheless, no significant interaction effect
between patient group and array was found (Table 3,
label:chip effect) and none of the peaks that could differ-
entiate between the arrays could differentiate between
cancer and control. The chip effect is almost absent in
Q10 Cromwell processed data. This provides compelling
evidence that our spectral alignment extension of
Cromwell can correct for the misalignment caused by per-
array calibration. Chip effects are also present in the Gau-
cher dataset, irrespective of the pre-processing method
used. However, these effects are caused by just one Gau-
cher patient sample and removing the sample from the
dataset removes chip effects (data not shown). Since there
Peak detected by Cromwell at 9740 Da (ovarian cancer dataset)Figure 3
Peak detected by Cromwell at 9740 Da (ovarian cancer dataset). A: plot of the mean raw spectrum of a peak 
detected by Cromwell (setting C) and not by Ciphergen (setting C). B: dot plot of the 9740 Da peak per sample group 
(Cromwell, setting C).
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Proteome Science 2009, 7:19 http://www.proteomesci.com/content/7/1/19was almost no interaction effect between patient group
and array, we decided to leave this sample in.
The ANOVA results in Table 3 seem to indicate that for the
ovarian cancer dataset – at least for CM10 and CM10/Q10
– Cromwell detects more differentially expressed peaks.
Since the total number of peaks detected by Cromwell and
Ciphergen using matched settings is smaller (Table 2),
this could have been mainly caused by a different multi-
plicity correction. Therefore, the results in terms of unad-
justed p-values are given in Figure 4 (see also Additional
Files 3, Additional File 4 and Additional File 5 for other
chip types and the Gaucher disease dataset). This confirms
the observed trend, although differences are small espe-
cially in the range of p-values smaller than 0.01. The over-
lap between the most differentially expressed peaks
detected by either Ciphergen or Cromwell is again large
(Table 4). Moreover, the fold changes estimated by either
method agree well.
A notable difference between the two methods is the way
in which the peak intensities are estimated. Ciphergen
takes a two-pass approach to find peaks. If a peak is found
in a minimum number of spectra (as determined by the
Min Peak Threshold parameter) within a certain mass
window, intensities are assigned to spectra without a peak
by taking their intensity at the average m/z value of the
cluster. In general, this extrapolation will not correspond
to a peak in a spectrum. Looking at the peaks with small
adjusted p-values as given by the ANOVA (Table 4), the
proportion of estimated intensities for a cluster can be as
high as ~50%. This is, for example, the case for the
28143Da peak detected on Q10 (Ciphergen C, ovarian
cancer dataset). Cromwell does not rely on extrapolated
intensities since it locates a local maximum in each pre-
processed spectrum. As a consequence, the Ciphergen
software assigns different intensities for one and the same
m/z value with different peak detection settings, whereas
the Cromwell package always assigns the same intensity
independent of the peak detection settings. This might
explain some of the observed differences.
Classification: Ciphergen pre-processed data
Classification was done using five different classification
methods on both datasets and all configurations. For clar-
ity, results for only one specific setting are summarized in
Tables 5 and 6, they are however representative for the
overall results (see Additional File 6 and Additional File
7). Classification of the Ciphergen pre-processed datasets
was better than chance in the majority of cases (Tables 5
and 6, confidence intervals not including 50%). For the
ovarian cancer dataset, the best classification result was
obtained on the combined CM10/Q10 data using DLDA
or SVM with a mean accuracy on 1000 randomly sampled
test sets of 77% (CI: 57–93). There is a large difference in
average accuracy depending on the model used, with
DLDA giving an 8% higher accuracy than classification
trees on the CM10/Q10 data. Combining CM10 and Q10
datasets into a CM10/Q10 dataset is beneficial and
increases the mean classification accuracy with on average
4% when compared to the maximum of the results on the
individual datasets (Table 5). Classification on CM10 data
outperforms Q10 data which is in agreement with the
lower number of differentially expressed peaks detected
for Q10 (Table 3). For the Gaucher dataset, the best clas-
sification result was obtained using SVM with a mean
accuracy on 500 randomly sampled test sets of 90% (CI:
75–100). Again there is a large difference in average accu-
racy between the various models with naive Bayes giving
a 17% lower accuracy than SVM.
We also varied the training set size to investigate its influ-
ence on the accuracy of the classifier. Figure 5 shows the
mean accuracy and its 95% CI as a function of the training
set size. Here and for all other cases (data not shown),
classification accuracy first increased with a larger training
set size and then stabilized.
Table 3: Differential expression
Ovarian cancer Gaucher
CM10 Q10 CM10/Q10
label Ciphergen A 43 19 57 57
Ciphergen B 37 15 47 46
Ciphergen C 41 13 50 30
chip Ciphergen A 6 57 69 8
Ciphergen B 10 35 52 7
Ciphergen C 0 15 16 10
label:chip Ciphergen A 0 0 0 3
Ciphergen B 0 0 0 0
Ciphergen C 0 0 0 0
label Cromwell A 153 17 142 43
Cromwell B 112 12 95 40
Cromwell C 67 8 61 29
chip Cromwell A 0 0 0 22
Cromwell B 0 0 0 37
Cromwell C 0 0 0 26
label:chip Cromwell A 0 0 0 1
Cromwell B 0 0 0 0
Cromwell C 0 0 0 0
Number of peaks with an adjusted p-value < 0,2 (ANOVA and 
correction for multiple testing) for different peak detection settings 
(A-C for both Ciphergen and Cromwell) for CM10, Q10, and CM10/
Q10 (ovarian cancer dataset) and the Gaucher dataset. An ANOVA 
was performed for label effect (patient versus control), chip (array) 
effect and interaction effect label:chip.Page 8 of 17
(page number not for citation purposes)
Proteome Science 2009, 7:19 http://www.proteomesci.com/content/7/1/19Different peak detection settings using Ciphergen pre-
processing had a considerable influence on classification
accuracy. For the ovarian cancer dataset more stringent
settings for peak detection, resulting in fewer detected
peaks, gave better overall accuracy. Use of feature selec-
tion also often led to better classification results in all of
the models used apart from SVMs (see Additional File 6).
For the Gaucher dataset, there is an opposite tendency of
less stringent settings giving better overall accuracy (see
Additional File 7).
Peak signatures for each of the random splits varied
greatly. A typical example of the individual m/z values
selected is given in Figure 6: only 16 peaks were included
in at least 300 of the 1000 signatures for the ovarian can-
cer data set. This list gives us candidate proteins with the
highest classification potential between ovarian cancer
and control patients. The most frequently selected peak at
2748 Da is clearly downregulated in the cancer samples
(Figure 2).
Classification: Cromwell pre-processed data
Classification of Cromwell pre-processed datasets gave
similar classification results as for Ciphergen (see Addi-
tional Files 6 and Additional File 7). Classification of the
Cromwell pre-processed datasets was better than chance
in the majority of cases. SVM, PCDA, and to a lesser (on
the Gaucher dataset) degree, DLDA again resulted in a
higher mean accuracy than naive Bayes and classification
trees. For the ovarian cancer dataset, combining CM10
and Q10 data led to increased mean accuracy. Classifica-
tion on CM10 data often outperforms Q10 data, in agree-
ment with the lower number of differentially expressed
peaks detected for Q10 (Table 3). We observed a decrease
in classification accuracy on both datasets when more
stringent pre-processing parameters were chosen. Use of
Table 4: Comparison of detected peaks (ovarian cancer dataset)
CM10
Peak
(Ciphergen)
logFC p-value adjusted p Peak
(Cromwell)
logFC p-value adjusted p cor
1546.06 -0.55 0.004 0.065 1540.24 -0.47 0.001 0.039 0.73
1555.67 -0.83 0.001 0.039 1552.28 -0.39 0.011 0.093 0.77
1584.26 -0.52 0.001 0.034 1540.24 -0.47 0.001 0.039 0.87
2648.88 -0.73 0.001 0.029 1540.24 -0.47 0.001 0.039 0.63
2747.67 -1.28 <0.001 0.008 2747.56 -1.06 0.001 0.039 0.95
2785.04 -1.21 <0.001 0.008 2785.52 -1.08 0.003 0.051 0.95
2824.21 -0.73 0.002 0.044 2823.75 -0.62 0.018 0.105 0.86
3164.30 -0.84 0.001 0.025 3163.52 -0.64 0.013 0.098 0.83
3403.11 -0.81 0.002 0.039 3402.37 -0.68 0.014 0.099 0.93
3441.36 -0.75 0.001 0.031 1615.29 -0.37 0.011 0.093 0.77
Q10
Peak
(Ciphergen)
logFC p-value adjusted p Peak
(Cromwell)
logFC p-value adjusted p cor
1721.35 -0.68 0.004 0.046 1511.76 -0.34 0.175 0.439 0.31
4078.66 -0.42 0.015 0.125 4079.56 -0.34 0.155 0.439 0.72
4273.34 -0.48 0.012 0.113 4274.66 -0.28 0.236 0.439 0.75
4287.14 -1.06 <0.001 0.005 4287.39 -0.92 0.009 0.143 0.88
6889.71 -1.02 0.001 0.014 6889.77 -1.43 0.004 0.103 0.92
8574.28 -1.47 <0.001 0.010 8572.2 -1.51 0.004 0.103 0.96
8703.04 -1.05 0.006 0.063 8700.12 -0.96 0.020 0.143 0.95
8772.14 -1.26 <0.001 0.001 8776.73 -1.35 0.004 0.103 0.91
13782.2 -1.11 0.002 0.029 6889.77 -1.43 0.004 0.103 0.91
28143.3 -0.77 0.016 0.125 8682.97 -1.09 0.015 0.143 0.75
List of ten most differentially expressed m/z values after pre-processing with either Ciphergen or Cromwell (setting C) for CM10 and Q10 
ProteinChip arrays. For each of the m/z values the log2 fold change (logFC), p-value and adjusted p-value are given. Peaks were matched between 
Ciphergen and Cromwell by calculating Pearson's correlation between a Ciphergen peak profile and all Cromwell peak profiles. The Cromwell peak 
with highest Pearson's correlation is considered to be a matching peak. Last column gives the corresponding correlation value.Page 9 of 17
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Cumulative plot of significance of detected peaks (ovarian cancer dataset)Figure 4
Cumulative plot of significance of detected peaks (ovarian cancer dataset). For each combination of pre-processing 
method and peak selection settings, the cumulative percentage of peaks with a p-value smaller than the value on the x-axis is 
shown. P-value of a peak is based on a t-test between the normalized intensities of the cancer and the control group. Inset 
zooms in on p-values smaller than 0.1. Dataset shown is the combined CM10/Q10 data.
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Table 5: Comparison of classifiers (ovarian cancer dataset)
Ciphergen C Cromwell A
CM10/Q10 CM10 Q10 CM10/Q10 CM10 Q10
DLDA 77 (57–93) 71 (50–93) 71 (50–86) 78 (64–93) 74 (57–93) 70 (43–93)
Naive Bayes 70 (50–93) 66 (43–86) 63 (43–86) 69 (50–86) 68 (50–86) 60 (36–86)
PCDA 73 (50–93) 70 (50–93) 67 (43–86) 77 (57–93) 73 (57–86) 77 (50–93)
SVM 77 (57–93) 71 (50–86) 70 (50–86) 79 (64–93) 77 (57–93) 79 (50–93)
Tree 69 (43–93) 69 (43–93) 64 (36–86) 58 (36–79) 58 (36–79) 52 (29–71)
Average classification accuracy (95% confidence interval) of ovarian cancer versus control on 1000 test sets (size of training sets: 14, size of test 
sets: 14). Pre-processing was done using setting C for Ciphergen and setting A for Cromwell. Classifiers without feature selection.
Proteome Science 2009, 7:19 http://www.proteomesci.com/content/7/1/19feature selection during classification did not show a clear
trend in terms of classification accuracy.
Classification: comparison of Ciphergen and Cromwell
To compare classifiers and pre-processing methods across
different datasets, they were ranked based on their average
accuracy. The outcome is visualized by heatmaps (Figure
7 and Figure 8, Additional File 8 and Additional File 9).
These heatmaps clearly illustrate the trends observed
above for each pre-processing method and dataset sepa-
rately. Differences in methodology between the pre-
processing methods are not reflected in a significant dif-
ference in classification accuracy. For both pre-processing
methods and datasets, PCDA, SVM, and to a lesser degree
DLDA, perform significantly better than naive Bayes and
classification trees. Also, results on CM10 and combined
CM10/Q10 data are significantly better than on Q10 data
(ovarian cancer dataset).
Discussion
In the two clinical studies described here, we have tried to
overcome some pre-analytical factors that influence the
protein profile in serum unrelated to disease. Careful
patient selection, matching for different biological varia-
bles and protocolized sample processing has led to data-
sets that have fewer variables that could bias the
classification outcome between patients and controls.
Next to issues concerning pre-analytical and analytical fac-
tors involved in proteomics, further challenges of mass
spectrometry are the pre-processing of spectra and statisti-
cal analysis of the detected m/z peaks in relatively small
sample sets. To reliably classify such datasets, sound bio-
informatics methods are needed that account for variation
arising from the biological samples as well as technical
variation introduced by sample handling and processing.
Table 6: Comparison of classifiers (Gaucher dataset)
Ciphergen C Cromwell B
DLDA 77 (50–100) 73 (50–92)
Naive Bayes 73 (50–92) 68 (42–92)
PCDA 81 (58–100) 81 (50–100)
SVM 90 (75–100) 86 (67–100)
Tree 75 (42–92) 72 (42–92)
Average classification accuracy (95% confidence interval) of Gaucher 
versus control on 500 test sets (size of training sets: 27, size of test 
sets: 12). Pre-processing was done using setting C for Ciphergen and 
setting B for Cromwell. Classifiers without feature selection.
Classification accuracy using repeated random resampling as a function f correspondi g training set sizesFigure 5
Classification accuracy using repeated random resa-
mpling as a function of corresponding training set 
sizes. Average classification accuracy (black line) of ovarian 
cancer versus control with its 95% confidence interval (red 
lines) on 1000 test sets as a function of training set size. 
Dataset used is the CM10 data with Ciphergen pre-process-
ing (setting C) with a DLDA classifier and feature selection.
Histogram of frequently selected peaksFigure 6
Histogram of frequently selected peaks. Peaks (m/z 
value) selected at least 300 times in 1000 signatures in classi-
fication of ovarian cancer versus control. Dataset used is the 
CM10 data with Ciphergen pre-processing (setting C) with a 
DLDA classifier and feature selection.Page 11 of 17
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Proteome Science 2009, 7:19 http://www.proteomesci.com/content/7/1/19Previous comparisons of pre-processing methods were
based on the use of tightly controlled calibration (or
spike-in) data, quality control data [18], or simulated data
[18,19]. Such datasets are highly relevant but capture only
part of the complexity observed in clinical samples typi-
cally profiled on a mass spectrometer. Moreover, recent
benchmark studies focused on comparing pre-processing
methods with respect to reproducibility and peak detec-
tion. While these are important criteria, it is clear that they
do not capture all objectives a good pre-processing
method should satisfy. For example, it is easy to minimize
the coefficient of variation by eliminating differences
between peak intensities across samples even if differ-
ences are biologically real. Therefore, we compared two
pre-processing methods in a classification setting using
Comparison of classifiers and pre-processing methods (ovarian cancer dataset)Figure 7
Comparison of classifiers and pre-processing methods (ovarian cancer dataset). Classifiers were ranked by their 
average classification accuracy on 1000 test sets (size of training sets: 14, size of test sets: 14) for each specific combination of 
chip type, pre-processing method and peak selection settings. The heatmap gives a colour coding of the ranks from 1 (highest 
accuracy, red) to 10 (lowest accuracy, light yellow). Classifiers are ordered by their average rank over all combinations, with 
DLDA being the best ranked classifier. The columns of the heatmap are ranked by their average rank over all classifiers, with 
Ciphergen pre-processing using setting C and the combined CM10/Q10 data getting the highest rank (see also Additional File 
8).Page 12 of 17
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Proteome Science 2009, 7:19 http://www.proteomesci.com/content/7/1/19five methods on two in-house generated clinical SELDI-
TOF MS datasets.
Our comparison of pre-processing methods consisted of
the commercial ProteinChip Software of Ciphergen and
the mean spectrum approach of Cromwell, a set of pub-
licly available Matlab scripts. While these and other pre-
processing methods described in the literature consist of
the same basic ingredients (smoothing, baseline subtrac-
tion, normalization, peak detection, peak clustering, and
peak quantification), the combination of these steps is
very different between Ciphergen and Cromwell (see
description in Patients, Materials, and Methods). Despite
these differences our results indicate that with respect to
reproducibility, Ciphergen and Cromwell pre-processing
are largely comparable. A recent comparison of various
pre-processing algorithms including Ciphergen and
Cromwell on quality control data also concluded that, at
least for these two pre-processing methods, the difference
in reproducibility is small [18]. A comparison of Cipher-
gen and Cromwell's direct precursor (SUDWT) [5] on
quality control data claimed that the reproducibility of
Ciphergen pre-processing was significantly lower. How-
ever, with their default Ciphergen parameter settings a
peak only had to occur in 15% ('Min Peak Threshold') of
the spectra to form a peak cluster. Given that Ciphergen
determines intensities for missing peaks by extrapolation,
a low reproducibility is a direct consequence of such a low
threshold. Since our goal is the identification of (a combi-
nation of) reliable biomarkers that can discriminate dis-
eased and controls, in this study a peak had to occur in at
least 30–40% of the spectra for almost all pre-processing
settings (Table 1).
Comparison of classifiers and pre-processing methods (Gaucher dataset)Figure 8
Comparison of classifiers and pre-processing methods (Gaucher dataset). Classifiers were ranked by their average 
classification accuracy on 500 test sets (size of training sets: 27, size of test sets: 12) for each specific combination of pre-
processing method and peak selection settings. The heatmap gives a colour coding of the ranks from 1 (highest accuracy, red) 
to 10 (lowest accuracy, light yellow). Classifiers are ordered by their average rank over all combinations, with SVM being the 
best ranked classifier. The columns of the heatmap are ranked by their average rank over all classifiers, with Ciphergen pre-
processing using setting A getting the highest rank (see also Additional File 9).
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Proteome Science 2009, 7:19 http://www.proteomesci.com/content/7/1/19Regarding peak detection we found that the overlap
between peaks detected by either Ciphergen or Cromwell
is large. This was especially the case for the more stringent
peak detection settings. Moreover, similarity of the esti-
mated intensities between matched peaks was high. Also
the overlap between the most differentially expressed
peaks detected by either Ciphergen or Cromwell is large
(Table 4) and estimated fold changes agree well across
methods. These results are comparable to those of Cruz-
Marcelo et al. [18] who found that peak detection with
Ciphergen was only slightly more sensitive than with
Cromwell for a range of false discovery rates on a simu-
lated data set. The main difference with our comparison is
that we used clinical datasets where the 'ground truth',
that is the number and location of true peaks, is not
known.
As stated above, clinical datasets lack a gold standard that
tells us the location of true peaks. However, they in gen-
eral consist of patient samples of known types or classes.
Prediction of patient status therefore offers a highly rele-
vant benchmark for comparison of pre-processing meth-
ods on a measurable and objective goal, namely
maximization of classification accuracy. We compared
five different classification methods and two pre-process-
ing methods on an ovarian cancer and a Gaucher disease
dataset generated with two types of ProteinChips. Special
care was taken to adequately validate the resulting classi-
fiers. We randomly sampled multiple training and test sets
for a range of training set sizes to study the stability of the
classifier accuracy. A nested cross-validation procedure
was used to simultaneously optimize the number of peaks
included in the model and provide an almost unbiased
estimate of the true error.
Regarding classification, we conclude that PCDA, SVM,
and to a lesser degree DLDA, perform significantly better
on all our datasets than naive Bayes and classification
trees. A similar observation has been made in a recent
comparison of normalization methods for SELDI-TOF MS
datasets [23]. In that study SVMs also perform signifi-
cantly better than classification trees. Moreover, using
DLDA, PCDA and SVM almost always led to better than
chance classification.
When comparing the classification results from the data-
sets pre-processed by the two different pre-processing
methods, no pre-processing method significantly outper-
forms the other for all peak detection settings evaluated.
However, significant differences are detected within and
between pre-processing methods for specific settings. For
example, Ciphergen pre-processing with stringent settings
(C) on the CM10/Q10 ovarian cancer dataset significantly
outperforms Cromwell with stringent settings. Previous
comparisons of pre-processing methods were based on
one specific parameter setting for each method, see for
example [18]. Therefore, they might have detected signif-
icant differences caused by a sub-optimal choice of
parameter settings for one of the methods compared.
Given the large impact of different settings for preprocess-
ing parameters on the overall outcome of classification,
evaluating a range of parameter settings should therefore
be a routine part of the pre-processing procedure.
In this study, we did not identify the proteins correspond-
ing to the discriminatory peaks, since our focus was on the
comparison of different pre-processing and classification
methods. Although one does not need to know the pro-
tein behind a discriminatory peak for accurate classifica-
tion, identification of such peaks does give us important
additional information. It will help us understand their
connection to a specific type of disease and help us dis-
criminate disease-related proteins from artifacts created,
for example, during sample preparation.
Conclusion
We have found that careful patient selection in combina-
tion with stringent sampling protocols generates datasets
that are suitable for further investigation. Our systematic
comparison of two different pre-processing methods
using five different classification methods has shown that
different pre-processing parameter settings lead to signifi-
cantly different classification results within and between
pre-processing methods. However, for both pre-process-
ing methods, settings could be found that gave compara-
ble maximal classification accuracy on an ovarian cancer
and a Gaucher disease dataset. Therefore, we advocate
evaluation over a range of different parameter settings
when comparing pre-processing methods for mass-spec-
trometry generated datasets such as SELDI-TOF MS data-
sets. Also the choice of a suitable classification method is
of vital importance for a good classification outcome. Our
comparison indicated that PCDA, SVM, and to a lesser
degree DLDA, outperform naive Bayes and classification
trees, at least on our two datasets.
Comparing different pre-processing methods and param-
eter settings using maximization of classification accuracy
on clinical datasets as prime objective does not only give
insight in the quality and reproducibility of the data, but
also indicates which pre-processing methods and settings
are best suited for a particular dataset. Given the abun-
dance of clinical mass spectrometry generated datasets, a
classification-based comparison of pre-processing meth-
ods on clinical data is a valuable complement to the use
of calibration or simulated data for that purpose.
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Additional file 1
Variance analysis (ovarian cancer dataset). Boxplots of the coefficient 
of variation (CV, standard deviation/mean peak intensity). Left panel: 
CV for all combinations of pre-processing method (Ciphergen: cyan, 
Cromwell: red) and peak selection setting (A, B, C) for the CM10 chip. 
Right panel: idem for Q10 chip.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
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Additional file 2
Variance analysis (Gaucher dataset). Boxplots of the coefficient of var-
iation (CV, standard deviation/mean peak intensity). CV for all combi-
nations of pre-processing method (Ciphergen: cyan, Cromwell: red) and 
peak selection setting (A, B, C).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-7-19-S2.pdf]
Additional file 3
Cumulative plot of significance of detected peaks (ovarian cancer 
dataset. CM10). For each combination of pre-processing method and 
peak selection settings, the cumulative percentage of peaks with a p-value 
smaller than the value on the x-axis are shown. P-value of a peak is based 
on a t-test between the normalized intensities of the cancer and the control 
group.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-7-19-S3.pdf]
Additional file 4
Cumulative plot of significance of detected peaks (ovarian cancer 
dataset, Q10). For each combination of pre-processing method and peak 
selection settings, the cumulative percentage of peaks with a p-value 
smaller than the value on the x-axis is shown. P-value of a peak is based 
on a t-test between the normalized intensities of the cancer and the control 
group.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-7-19-S4.pdf]
Additional file 5
Cumulative plot of significance of detected peaks (Gaucher dataset). 
For each combination of pre-processing method and peak selection set-
tings, the cumulative percentage of peaks with a p-value smaller than the 
value on the x-axis is shown. P-value of a peak is based on a t-test between 
the normalized intensities of the Gaucher and the control group.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-7-19-S5.pdf]
Additional file 6
Comparison of classifiers and pre-processing methods (ovarian cancer 
dataset). Average classification accuracy on 1000 test sets (size of train-
ing sets: 14, size of test sets: 14) for each specific combination of pre-
processing method and peak selection settings.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-7-19-S6.xls]
Additional file 7
Comparison of classifiers and pre-processing methods (Gaucher data-
set). Average classification accuracy on 500 test sets (size of training sets: 
27, size of test sets: 12) for each specific combination of pre-processing 
method and peak selection settings.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
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Comparison of classifiers and pre-processing methods (ovarian cancer 
dataset). Each combination of chip type, pre-processing method and peak 
selection was ranked by its average classification accuracy on 1,000 test 
sets (size of training sets: 14, size of test sets: 14) for each classifier. The 
heatmap gives a colour coding of the ranks from 1 (highest accuracy, red) 
to 18 (lowest accuracy, light yellow). Columns of the heatmap are ranked 
by their average rank over all classifiers, with Ciphergen pre-processing 
using setting C and the combined CM10/Q10 data getting the highest 
rank. Classifiers are ordered by their average rank over all pre-processing 
combinations, with DLDA being the best ranked classifier.
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accuracy, light yellow). Columns of the heatmap are ranked by their aver-
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